Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Active Biotech AB ( (SE:ACTI) ) has provided an update.
Active Biotech announced that its patent for a pharmaceutical formulation of tasquinimod will be granted in the US, providing protection and market exclusivity until 2042. This development is a significant step in the company’s strategy to enhance global protection for tasquinimod, which is being developed for hematological malignancies and has shown therapeutic potential in multiple myeloma and myelofibrosis. The patent grant is expected to strengthen Active Biotech’s position in the biotechnology industry, particularly in oncology and immunology, and may have positive implications for stakeholders by potentially increasing the company’s market share and competitive edge.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical needs and significant commercial potential. The company has three projects in its portfolio, including tasquinimod and laquinimod, which are small molecule immunomodulators. Active Biotech is primarily focused on developing tasquinimod for myelofibrosis, a rare blood cancer, and has initiated clinical proof-of-concept studies in this area. Laquinimod is being developed for non-infectious uveitis, and naptumomab is in development for advanced solid tumors in partnership with NeoTX Therapeutics.
Average Trading Volume: 6,555,902
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK171.3M
Find detailed analytics on ACTI stock on TipRanks’ Stock Analysis page.